Perimenopause Depression

Can Perimenopause Cause Depression?

Perimenopause does not cause depression in everyone, and most women go through it without a depressive episode. But research consistently shows that the menopause transition and the years just after it are a time of higher risk. Several long-term studies have found that women are about 2 to 4 times more likely to have a major depressive episode or significant depressive symptoms during this window than before it.

If you have had depression before, including postpartum depression or PMDD, this is especially worth knowing, because a history of depression is the strongest predictor of depression in midlife. The good news is that perimenopausal depression is recognized, and it is treatable.

What Is Perimenopause?

Perimenopause is the time around menopause when the body shifts from regular menstrual cycles toward the final period. According to the STRAW+10 staging system used by researchers and clinicians:

  • It begins when cycle length starts to vary, with consecutive cycles differing by 7 days or more.
  • The later part, when periods are skipped for longer stretches, lasts on average 1 to 3 years.
  • It ends 12 months after the final menstrual period, which is when menopause is confirmed.

In a large U.S. study, the median age at the final period was about 52.5, with no difference across racial and ethnic groups. Symptoms often last longer than people expect: hot flashes and night sweats lasted a median of 7.4 years in women who had frequent symptoms, and continued a median of 4.5 years after the final period.

How Much Does Depression Risk Rise?

  • In the Study of Women’s Health Across the Nation (SWAN), which used diagnostic interviews, women were 2 to 4 times more likely to have a major depressive episode during perimenopause or early postmenopause. This held even after accounting for past depression, stressful events, hot flashes and hormone levels.
  • In the Harvard Study of Moods and Cycles, women with no history of depression at all were twice as likely to develop significant depressive symptoms once they entered perimenopause.
  • In a Danish national study of more than 270,000 women, 2.9% were diagnosed with depression during perimenopause over about nine years. That base rate is a helpful reminder that higher relative risk is not the same as a high chance for any one person.

Studies don’t fully agree on exactly when risk peaks. Some find it highest during perimenopause itself, while a larger SWAN symptom analysis found higher odds after menopause but not during perimenopause. The fairest summary is that risk rises across the transition and the years right after it.

Who Is at Higher Risk?

  • A past episode of depression. This is the strongest risk factor. In one SWAN analysis, 59% of women with a prior major depression had another episode during midlife, compared with 28% of those without one.
  • Family history of depression.
  • Hot flashes and night sweats, particularly for a first-ever episode.
  • Poor sleep. Insomnia and depression feed each other in both directions.
  • Stressful life events and low social support.
  • Childhood adversity, such as two or more adverse childhood experiences.
  • Surgical menopause. In women who had their ovaries removed to lower cancer risk, depressive symptoms rose in the first year and were no longer elevated by two years for most, though those with high symptoms at one year were much more likely to still have them.
  • Bipolar disorder or prior depression carries a known risk of relapse during the transition.

Postpartum Depression, PMDD and Perimenopause

Many women who had postpartum depression or PMDD wonder whether they are more vulnerable to mood changes at menopause. The research gives a nuanced answer.

  • Any history of depression raises risk a lot. In the Danish national study, a history of postpartum depression was linked to about 13 times the rate of depression during perimenopause, and depression at other times was linked to about 12 times the rate.
  • In that large study, postpartum depression was not a special risk beyond other kinds of past depression.
  • A smaller 2026 clinic study found something different. Among 180 women at menopause clinics, a history of premenstrual mood disorder or perinatal depression was linked to more severe depressive symptoms during the transition, while depression unrelated to reproductive events was not.

Researchers have proposed that some women are especially sensitive to hormone fluctuations across puberty, the menstrual cycle, pregnancy and perimenopause, possibly through effects on the brain’s GABA and stress systems. This is a promising theory, but it has not been proven. The practical message is the same either way: if you’ve had postpartum depression, PMDD or any depression, tell your clinician as you approach perimenopause so you can plan ahead.

Symptoms of Perimenopausal Depression

Perimenopausal depression includes the classic symptoms of depression, often mixed with menopause symptoms:

  • Persistent low mood, sadness or emptiness
  • Loss of interest or pleasure
  • Irritability or feeling on edge
  • Low energy and fatigue
  • Sleep problems, often tangled up with night sweats
  • Trouble concentrating or remembering, which many women describe as brain fog
  • Feelings of worthlessness or guilt
  • Changes in appetite or sex drive
  • Thoughts of death or suicide

Because hot flashes, poor sleep and fatigue overlap with depression, it can be hard to tell what is driving what. Other conditions can also cause similar symptoms, so your clinician may check thyroid function and other health issues.

You can take the PHQ-9 depression questionnaire in a few minutes and share the result with your doctor.

How It Is Diagnosed

A 2018 guideline from an expert panel convened by The North American Menopause Society (now The Menopause Society) and the National Network of Depression Centers recommends:

  • Identifying where you are in the menopause transition
  • Assessing both mood symptoms and menopause symptoms
  • Considering midlife stresses and other possible causes
  • Using validated screening questionnaires

A perimenopause-specific scale, the Meno-D, has been developed and validated in a small study, but general depression questionnaires are more widely used.

Treatment for Perimenopausal Depression

Antidepressants and Therapy Come First

The 2018 guideline states that proven depression treatments, antidepressants and psychotherapy, are the front-line treatments for perimenopausal depression.

  • In a randomized trial of peri- and postmenopausal women with major depression, the SNRI desvenlafaxine reduced depression scores more than placebo.
  • Cognitive behavioral therapy (CBT) for menopause symptoms has improved depressive symptoms in trials, though many used waitlist comparisons rather than active treatments.
  • Mindfulness-based stress reduction lowered depressive symptoms, stress and anxiety in a randomized trial of women in midlife, but did not reduce the number of major depressive episodes.

Find a therapist who treats women’s mental health across life stages

Hormone Therapy

Hormone therapy is not FDA-approved to treat depression, but there is evidence it can help some women.

  • In a small NIMH trial, 68% of perimenopausal women with depression treated with an estradiol patch reached remission, compared with 20% on placebo.
  • In a trial of women without depression, estradiol with progesterone reduced new depressive symptoms over a year (17% vs. 32%), but only for women in the early menopause transition, not later or after menopause.
  • A 2026 review pooling 12 trials found only a small average effect of hormone therapy on depressive symptoms, with low certainty.

The 2018 guideline notes that estrogen’s antidepressant effects appear strongest in women who also have hot flashes, and that evidence for estrogen plus progestin is limited. Whether hormone therapy is right for you depends on your health history and should be decided with your doctor.

Exercise and Sleep

  • A meta-analysis of 16 trials found exercise significantly reduced depressive symptoms in menopausal women, with larger effects for mind-body exercise such as yoga or tai chi, longer programs and women in perimenopause.
  • Treating insomnia may help break the cycle between poor sleep and low mood.

What About Supplements?

The Menopause Society’s 2023 statement on nonhormonal treatment does not recommend supplements or herbal remedies for hot flashes. Some older, small studies reported mood benefits from remedies like St. John’s wort, but the evidence is limited, and St. John’s wort interacts with many medications. Fezolinetant, a newer nonhormonal drug, is approved for hot flashes, not depression.

When to Get Help

Talk to your doctor if low mood, irritability or loss of interest lasts more than two weeks or is affecting your work, relationships or daily life. Women ages 45 to 64 have the highest suicide rate of any female age group in the U.S., according to CDC data, so thoughts of suicide should always be taken seriously.

If you are having thoughts of suicide or harming yourself, call or text 988 for the 988 Suicide & Crisis Lifeline, available 24 hours a day. In an emergency, call 911.

Frequently Asked Questions

Can perimenopause cause depression?

Perimenopause raises the risk of depression, about 2 to 4 times in several studies, but it does not cause depression in most women. Past depression, sleep problems, hot flashes and stress all add to risk.

How do I know if it’s perimenopause or depression?

They often overlap. Depression involves persistent low mood or loss of interest for at least two weeks. A clinician can look at your cycle changes, menopause symptoms and mood together and rule out other causes such as thyroid problems.

Does hormone therapy help perimenopausal depression?

It can help some women, especially in early perimenopause and those with hot flashes, but it is not FDA-approved for depression and the average effect across trials is small. Antidepressants and therapy are first-line.

Does having postpartum depression make perimenopausal depression more likely?

Any history of depression, including postpartum depression, greatly increases risk. A large Danish study found postpartum depression was not a bigger risk than other past depression, while a smaller clinic study suggested reproductive-related mood history may matter more.

How long does perimenopausal depression last?

It varies. With treatment, most depression improves. Menopause symptoms like hot flashes can last several years, so ongoing check-ins are helpful.

What is the best antidepressant for perimenopause?

There is no single best choice. SSRIs and SNRIs are commonly used, and some also reduce hot flashes. Your prescriber will consider your symptoms, history and other medications.

PostpartumDepression.org Team
Written by:

Jenna Carberg was diagnosed with postpartum depression following the birth of her daughter in 2016. It was a healthy birth but in the following days, Jenna's mood changed quickly. Doctors suggested that it might be the "baby blues", but her husband Chris suggested she seek a second opinion. Jenna was diagnosed with postpartum depression and began a journey that lasted 9 long months with significant ups and downs. Jenna's mental health care and her experiences became a passion for her to share with the world. She and her husband Chris founded PostpartumDepression.org as a support website designed to help women suffering in silence and their loved ones.

  1. Harlow SD, Gass M, Hall JE, et al. “Executive summary of the Stages of Reproductive Aging Workshop + 10: Addressing the unfinished agenda of staging reproductive aging.” Journal of Clinical Endocrinology and Metabolism. 2012;97(4):1159-1168. https://doi.org/10.1210/jc.2011-3362.
  2. Huibregtse ME, Taylor L, Prochaska T, et al. “Considerations and practical recommendations for identifying perimenopause in longitudinal research.” Psychoneuroendocrinology. 2026;186:107748. https://doi.org/10.1016/j.psyneuen.2026.107748.
  3. Gold EB, Crawford SL, Avis NE, et al. “Factors related to age at natural menopause: Longitudinal analyses from SWAN.” American Journal of Epidemiology. 2013;178(1):70-83. https://doi.org/10.1093/aje/kws421.
  4. Avis NE, Crawford SL, Greendale G, et al. “Duration of menopausal vasomotor symptoms over the menopause transition.” JAMA Internal Medicine. 2015;175(4):531-539. https://doi.org/10.1001/jamainternmed.2014.8063.
  5. Bromberger JT, Kravitz HM, Chang YF, et al. “Major depression during and after the menopausal transition: Study of Women’s Health Across the Nation (SWAN).” Psychological Medicine. 2011;41(9):1879-1888. https://doi.org/10.1017/S003329171100016X.
  6. Bromberger JT, Kravitz HM. “Mood and menopause: Findings from the Study of Women’s Health Across the Nation (SWAN) over 10 years.” Obstetrics and Gynecology Clinics of North America. 2011;38(3):609-625. https://doi.org/10.1016/j.ogc.2011.05.011.
  7. Bromberger JT, Schott LL, Kravitz HM, et al. “Longitudinal change in reproductive hormones and depressive symptoms across the menopausal transition: Results from the Study of Women’s Health Across the Nation (SWAN).” Archives of General Psychiatry. 2010;67(6):598-607. https://doi.org/10.1001/archgenpsychiatry.2010.55.
  8. Kravitz HM, Colvin AB, Avis NE, et al. “Risk of high depressive symptoms after the final menstrual period: The Study of Women’s Health Across the Nation (SWAN).” Menopause. 2022;29(7):805-815. https://doi.org/10.1097/GME.0000000000001988.
  9. Cohen LS, Soares CN, Vitonis AF, et al. “Risk for new onset of depression during the menopausal transition: The Harvard Study of Moods and Cycles.” Archives of General Psychiatry. 2006;63(4):385-390. https://doi.org/10.1001/archpsyc.63.4.385.
  10. Musial N, Ali Z, Grbevski J, et al. “Perimenopause and first-onset mood disorders: A closer look.” Focus (American Psychiatric Publishing). 2021;19(3):330-337. https://doi.org/10.1176/appi.focus.20200041.
  11. Li Y, Sun Y, Bi Y, et al. “Efficacy and safety of menopausal hormone therapy for depressive symptoms in perimenopausal women: A systematic review and meta-analysis.” Journal of Affective Disorders. 2026;409:121892. https://doi.org/10.1016/j.jad.2026.121892.
  12. Epperson CN, Sammel MD, Bale TL, et al. “Adverse childhood experiences and risk for first-episode major depression during the menopause transition.” The Journal of Clinical Psychiatry. 2017;78(3):e298-e307. https://doi.org/10.4088/JCP.16m10662.
  13. Colvin A, Richardson GA, Cyranowski JM, et al. “The role of family history of depression and the menopausal transition in the development of major depression in midlife women: Study of Women’s Health Across the Nation Mental Health Study (SWAN MHS).” Depression and Anxiety. 2017;34(9):826-835. https://doi.org/10.1002/da.22651.
  14. Bromberger JT, Schott L, Kravitz HM, et al. “Risk factors for major depression during midlife among a community sample of women with and without prior major depression: Are they the same or different?” Psychological Medicine. 2015;45(8):1653-1664. https://doi.org/10.1017/S0033291714002773.
  15. Steinberg EM, Rubinow DR, Bartko JJ, et al. “A cross-sectional evaluation of perimenopausal depression.” The Journal of Clinical Psychiatry. 2008;69(6):973-980. https://doi.org/10.4088/jcp.v69n0614.
  16. Venborg E, Osler M, Jørgensen TSH. “The association between postpartum depression and perimenopausal depression: A nationwide register-based cohort study.” Maturitas. 2023;169:10-15. https://doi.org/10.1016/j.maturitas.2022.12.001.
  17. Schipper M, Morssinkhof MWL, van Dijken DKE, et al. “Prior reproductive and non-reproductive depression, and depressive symptoms in menopausal transition.” Journal of Affective Disorders. 2026;414:122361. https://doi.org/10.1016/j.jad.2026.122361.
  18. Stumper A, Schmalenberger KM, Eisenlohr-Moul TA, et al. “Affective sensitivity to ovarian steroid hormone flux across the menstrual cycle: Manifestations and biopsychosocial risk factors.” Annual Review of Clinical Psychology. 2026;22(1):77-104. https://doi.org/10.1146/annurev-clinpsy-061724-083756.
  19. Gordon JL, Girdler SS, Meltzer-Brody SE, et al. “Ovarian hormone fluctuation, neurosteroids, and HPA axis dysregulation in perimenopausal depression: A novel heuristic model.” The American Journal of Psychiatry. 2015;172(3):227-236. https://doi.org/10.1176/appi.ajp.2014.14070918.
  20. Gordon JL, Sander B. “The role of estradiol fluctuation in the pathophysiology of perimenopausal depression: A hypothesis paper.” Psychoneuroendocrinology. 2021;133:105418. https://doi.org/10.1016/j.psyneuen.2021.105418.
  21. Willi J, Ehlert U. “Symptoms assessed in studies on perimenopausal depression: A narrative review.” Sexual & Reproductive Healthcare. 2020;26:100559. https://doi.org/10.1016/j.srhc.2020.100559.
  22. Panda S, Das A. “Analyzing thyroid dysfunction in the climacteric.” Journal of Mid-Life Health. 2018;9(3):113-116. https://doi.org/10.4103/jmh.JMH_21_18.
  23. Maki PM, Kornstein SG, Joffe H, et al. “Guidelines for the evaluation and treatment of perimenopausal depression: Summary and recommendations.” Menopause. 2018;25(10):1069-1085. https://doi.org/10.1097/GME.0000000000001174.
  24. Kulkarni J, Gavrilidis E, Hudaib AR, et al. “Development and validation of a new rating scale for perimenopausal depression – the Meno-D.” Translational Psychiatry. 2018;8(1):123. https://doi.org/10.1038/s41398-018-0172-0.
  25. Kulkarni J, Cashell C, Harvey E, et al. “The primary care management of perimenopausal depression.” Australian Journal of General Practice. 2026;55(4):197-202. https://doi.org/10.31128/AJGP-08-25-7774.
  26. Gordon JL, Rubinow DR, Eisenlohr-Moul TA, et al. “Efficacy of transdermal estradiol and micronized progesterone in the prevention of depressive symptoms in the menopause transition: A randomized clinical trial.” JAMA Psychiatry. 2018;75(2):149-157. https://doi.org/10.1001/jamapsychiatry.2017.3998.
  27. Soares CN, Almeida OP, Joffe H, Cohen LS. “Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: A double-blind, randomized, placebo-controlled trial.” Archives of General Psychiatry. 2001;58(6):529-534. https://doi.org/10.1001/archpsyc.58.6.529.
  28. Soares CN, Arsenio H, Joffe H, et al. “Escitalopram versus ethinyl estradiol and norethindrone acetate for symptomatic peri- and postmenopausal women: Impact on depression, vasomotor symptoms, sleep, and quality of life.” Menopause. 2006;13(5):780-786. https://doi.org/10.1097/01.gme.0000240633.46300.fa.
  29. Clayton AH, Kornstein SG, Dunlop BW, et al. “Efficacy and safety of desvenlafaxine 50 mg/d in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder.” The Journal of Clinical Psychiatry. 2013;74(10):1010-1017. https://doi.org/10.4088/JCP.12m08065.
  30. Gordon JL, Halleran M, Beshai S, et al. “Endocrine and psychosocial moderators of mindfulness-based stress reduction for the prevention of perimenopausal depressive symptoms: A randomized controlled trial.” Psychoneuroendocrinology. 2021;130:105277. https://doi.org/10.1016/j.psyneuen.2021.105277.
  31. Li S, Dou Y, Li Y. “Exercise as a therapeutic strategy for depression in menopausal women: A meta-analysis of randomized trials.” Frontiers in Psychiatry. 2025;16:1641082. https://doi.org/10.3389/fpsyt.2025.1641082.
  32. Caruso D, Masci I, Cipollone G, Palla G. “Insomnia and depressive symptoms during the menopausal transition: Theoretical and therapeutic implications of a self-reinforcing feedback loop.” Maturitas. 2019;123:78-81. https://doi.org/10.1016/j.maturitas.2019.02.007.
  33. Pien GW, Sammel MD, Freeman EW, et al. “Predictors of sleep quality in women in the menopausal transition.” Sleep. 2008;31(7):991-999. https://doi.org/10.1093/sleep/31.7.991.
  34. Hickey M, Nguyen TL, Krejany EO, et al. “What happens after menopause? (WHAM): Impact of risk-reducing salpingo-oophorectomy on depressive and anxiety symptoms at 24 months.” Gynecologic Oncology. 2025;192:1-7. https://doi.org/10.1016/j.ygyno.2024.10.031.
  35. The North American Menopause Society Advisory Panel. “The 2022 hormone therapy position statement of The North American Menopause Society.” Menopause. 2022;29(7):767-794. https://doi.org/10.1097/GME.0000000000002028.
  36. The North American Menopause Society Advisory Panel. “The 2023 nonhormone therapy position statement of The North American Menopause Society.” Menopause. 2023;30(6):573-590. https://doi.org/10.1097/GME.0000000000002200.
  37. Garnett MF, Zehner AM. “Changes in Suicide Rates in the United States From 2022 to 2023.” NCHS Data Brief No. 541. National Center for Health Statistics. September 2025. https://ncbi.nlm.nih.gov/books/NBK618447.
  38. Substance Abuse and Mental Health Services Administration. “988 Suicide & Crisis Lifeline.” SAMHSA. Accessed September 15, 2026. https://samhsa.gov/mental-health/988.
  39. American College of Obstetricians and Gynecologists. “The Menopause Years (FAQ).” ACOG. Accessed September 15, 2026. https://acog.org/womens-health/faqs/the-menopause-years.
  40. Geller SE, Studee L. “Botanical and dietary supplements for mood and anxiety in menopausal women.” Menopause. 2007;14(3 Pt 1):541-549. https://doi.org/10.1097/01.gme.0000236934.43701.c5.